Switch to:
Also traded in: Germany, Israel

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash-to-Debt 0.28
MNKD's Cash-to-Debt is ranked lower than
92% of the 1056 Companies
in the Global Biotechnology industry.

( Industry Median: 73.06 vs. MNKD: 0.28 )
Ranked among companies with meaningful Cash-to-Debt only.
MNKD' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 0.31 Max: No Debt
Current: 0.28
0.01
No Debt
Equity-to-Asset -2.54
MNKD's Equity-to-Asset is ranked lower than
99% of the 770 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. MNKD: -2.54 )
Ranked among companies with meaningful Equity-to-Asset only.
MNKD' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.54  Med: -0.44 Max: 0.75
Current: -2.54
-2.54
0.75
Debt-to-Equity -0.73
MNKD's Debt-to-Equity is ranked lower than
99.99% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. MNKD: -0.73 )
Ranked among companies with meaningful Debt-to-Equity only.
MNKD' s Debt-to-Equity Range Over the Past 10 Years
Min: -8.15  Med: -0.77 Max: 1.64
Current: -0.73
-8.15
1.64
Debt-to-EBITDA -1.56
MNKD's Debt-to-EBITDA is ranked lower than
99.99% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. MNKD: -1.56 )
Ranked among companies with meaningful Debt-to-EBITDA only.
MNKD' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.9  Med: -1.51 Max: 1
Current: -1.56
-2.9
1
Piotroski F-Score: 1
Altman Z-Score: -51.14
Beneish M-Score: -12.04
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -805.11
MNKD's Operating Margin % is ranked lower than
75% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -98.02 vs. MNKD: -805.11 )
Ranked among companies with meaningful Operating Margin % only.
MNKD' s Operating Margin % Range Over the Past 10 Years
Min: -1528825  Med: -222527.17 Max: 35.95
Current: -805.11
-1528825
35.95
Net Margin % -999.00
MNKD's Net Margin % is ranked lower than
77% of the 800 Companies
in the Global Biotechnology industry.

( Industry Median: -88.19 vs. MNKD: -999.00 )
Ranked among companies with meaningful Net Margin % only.
MNKD' s Net Margin % Range Over the Past 10 Years
Min: -1515195  Med: -252502.93 Max: 71.91
Current: -999
-1515195
71.91
ROA % -142.16
MNKD's ROA % is ranked lower than
91% of the 1062 Companies
in the Global Biotechnology industry.

( Industry Median: -32.55 vs. MNKD: -142.16 )
Ranked among companies with meaningful ROA % only.
MNKD' s ROA % Range Over the Past 10 Years
Min: -142.16  Med: -74.24 Max: 107.65
Current: -142.16
-142.16
107.65
ROC (Joel Greenblatt) % -300.24
MNKD's ROC (Joel Greenblatt) % is ranked higher than
54% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -430.94 vs. MNKD: -300.24 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MNKD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -300.24  Med: -95.4 Max: 259.12
Current: -300.24
-300.24
259.12
3-Year EBITDA Growth Rate 22.50
MNKD's 3-Year EBITDA Growth Rate is ranked higher than
73% of the 722 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. MNKD: 22.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MNKD' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 25.6 Max: 43
Current: 22.5
0
43
3-Year EPS without NRI Growth Rate 24.00
MNKD's 3-Year EPS without NRI Growth Rate is ranked higher than
74% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. MNKD: 24.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MNKD' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 23.1 Max: 42.9
Current: 24
0
42.9
GuruFocus has detected 4 Warning Signs with MannKind Corp MNKD.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MNKD's 30-Y Financials

Financials (Next Earnings Date: 2018-05-10)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

MNKD Guru Trades in Q4 2016

Joel Greenblatt 90,068 sh (New)
Paul Tudor Jones 103,325 sh (unchged)
» More
Q1 2017

MNKD Guru Trades in Q1 2017

Joel Greenblatt 18,825 sh (+4.50%)
Paul Tudor Jones 20,665 sh (unchged)
» More
Q2 2017

MNKD Guru Trades in Q2 2017

Paul Tudor Jones 20,665 sh (unchged)
Joel Greenblatt Sold Out
» More
Q3 2017

MNKD Guru Trades in Q3 2017

Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NAS:MNKD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-06-30 Sold Out $0.71 - $1.65 $ 1.7334%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:AMEX:BTX, NAS:TORC, NAS:BSTC, NAS:SVRA, ROCO:4128, LSE:MPH, NAS:CBIO, LSE:HZD, OSL:NANO, XKRX:228760, NAS:CUE, XKRX:200670, TSX:ZYME, BOM:512529, NAS:NK, NAS:CLDX, XPAR:COX, NAS:MCRB, XKRX:001630, NAS:CRVS » details
Traded in other countries:NNFN.Germany, MNKD.Israel,
Headquarter Location:USA
MannKind Corp is engaged in the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and cancer. Its products and technologies include Afrezza, Dry powder formulation, Inhalation profiling, and others.

MannKind Corp is a biopharmaceutical company. It is involved in the business of discovery, development, and commercialization of therapeutic products and solutions for the patients with the diseases such as diabetes. Its products and technologies include Afrezza, Dry powder formulation, Inhalation profiling, Oral inhalers and others. The company has following products in the pipeline: Epinephrine technosphere, Treprostinil technosphere, and Palonosetron technosphere.

Ratios

vs
industry
vs
history
PS Ratio 15.45
MNKD's PS Ratio is ranked lower than
64% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. MNKD: 15.45 )
Ranked among companies with meaningful PS Ratio only.
MNKD' s PS Ratio Range Over the Past 10 Years
Min: 0.43  Med: 14450 Max: 71250
Current: 15.45
0.43
71250
EV-to-EBIT -3.35
MNKD's EV-to-EBIT is ranked lower than
99.99% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 24.43 vs. MNKD: -3.35 )
Ranked among companies with meaningful EV-to-EBIT only.
MNKD' s EV-to-EBIT Range Over the Past 10 Years
Min: -41.6  Med: -3.9 Max: 3.2
Current: -3.35
-41.6
3.2
EV-to-EBITDA -3.47
MNKD's EV-to-EBITDA is ranked lower than
99.99% of the 287 Companies
in the Global Biotechnology industry.

( Industry Median: 21.70 vs. MNKD: -3.47 )
Ranked among companies with meaningful EV-to-EBITDA only.
MNKD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -53.6  Med: -4.1 Max: 3.1
Current: -3.47
-53.6
3.1
EV-to-Revenue 29.80
MNKD's EV-to-Revenue is ranked lower than
66% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: 13.46 vs. MNKD: 29.80 )
Ranked among companies with meaningful EV-to-Revenue only.
MNKD' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.1  Med: 21476.7 Max: 90639.2
Current: 29.8
1.1
90639.2
Current Ratio 0.65
MNKD's Current Ratio is ranked lower than
93% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. MNKD: 0.65 )
Ranked among companies with meaningful Current Ratio only.
MNKD' s Current Ratio Range Over the Past 10 Years
Min: 0.23  Med: 1.16 Max: 10
Current: 0.65
0.23
10
Quick Ratio 0.62
MNKD's Quick Ratio is ranked lower than
91% of the 1035 Companies
in the Global Biotechnology industry.

( Industry Median: 3.92 vs. MNKD: 0.62 )
Ranked among companies with meaningful Quick Ratio only.
MNKD' s Quick Ratio Range Over the Past 10 Years
Min: 0.23  Med: 1.16 Max: 10
Current: 0.62
0.23
10
Days Inventory 63.51
MNKD's Days Inventory is ranked higher than
73% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: 126.17 vs. MNKD: 63.51 )
Ranked among companies with meaningful Days Inventory only.
MNKD' s Days Inventory Range Over the Past 10 Years
Min: 8.49  Med: 27.26 Max: 63.51
Current: 63.51
8.49
63.51
Days Sales Outstanding 56.06
MNKD's Days Sales Outstanding is ranked lower than
67% of the 656 Companies
in the Global Biotechnology industry.

( Industry Median: 64.11 vs. MNKD: 56.06 )
Ranked among companies with meaningful Days Sales Outstanding only.
MNKD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.06  Med: 2378.34 Max: 4692.86
Current: 56.06
56.06
4692.86
Days Payable 147.97
MNKD's Days Payable is ranked higher than
75% of the 456 Companies
in the Global Biotechnology industry.

( Industry Median: 62.86 vs. MNKD: 147.97 )
Ranked among companies with meaningful Days Payable only.
MNKD' s Days Payable Range Over the Past 10 Years
Min: 23.78  Med: 87.94 Max: 147.97
Current: 147.97
23.78
147.97

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -13.60
MNKD's 3-Year Average Share Buyback Ratio is ranked higher than
63% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. MNKD: -13.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MNKD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -58.3  Med: -36.3 Max: -8
Current: -13.6
-58.3
-8

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) % -29.77
MNKD's Earnings Yield (Greenblatt) % is ranked lower than
75% of the 1060 Companies
in the Global Biotechnology industry.

( Industry Median: -6.86 vs. MNKD: -29.77 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MNKD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -523.3  Med: -18.4 Max: 80.6
Current: -29.77
-523.3
80.6

More Statistics

Revenue (TTM) (Mil) $11.75
EPS (TTM) $ -1.12
Beta3.12
Volatility123.84%
52-Week Range $0.67 - 6.96
Shares Outstanding (Mil)137.01

Piotroski F-Score Details

Piotroski F-Score: 11
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}